Exagen Inc. (Nasdaq: XGN) jumps 25.42% to $3.70 after posting record Q1 2026 Revenue of $17.3 million, up 12% year-over-year, driven by strong AVISE CTD testing Volume and higher average selling prices, while maintaining full-year guidance of $70-$73 million.

Key Highlights

  • XGN up +25.42% to $3.70, surging $0.75 in one of Tuesday's standout moves
  • Record Q1 2026 revenue of $17.3 million, up 12% year-over-year
  • AVISE CTD testing volume continues to grow, driven by rheumatology adoption
  • Higher average selling prices contributing to revenue mix improvement
  • Adjusted EBITDA trajectory improving quarter over quarter
  • Full-year 2026 revenue guidance maintained at $70-$73 million

Exagen Inc. (NASDAQ: XGN) surged 25.42 per cent to $3.70 on Tuesday after the medical diagnostics company reported a first quarter that exceeded expectations on the metrics that matter most for a diagnostics Business at this stage of its commercial development: volume, pricing, and the trajectory of profitability. The combination of record revenue, improving EBITDA, and maintained annual guidance was sufficient to catalyse a re-rating that, while dramatic in percentage terms, reflects the market catching up to an operational story that has been building quietly for several quarters.

First-quarter revenue of $17.3 million represented a 12 per cent increase over the same period a year earlier, driven by continued growth in AVISE CTD testing volume and higher average selling prices across the test menu. AVISE CTD — the company's proprietary multi-biomarker test for the evaluation of connective tissue diseases including systemic lupus erythematosus — is the Franchise asset around which Exagen has built its commercial infrastructure and its clinical differentiation narrative.

Connective tissue disease diagnosis is notoriously challenging. Systemic lupus erythematosus, in particular, is a disease of protean clinical manifestations that frequently mimics other conditions, leading to an average diagnostic delay of several years in many patient populations. AVISE CTD's multi-biomarker approach — incorporating anti-dsDNA, cell-bound complement activation products, and other markers — is designed to provide a more complete biological picture of disease activity than individual tests alone, supporting earlier and more accurate diagnosis and enabling more targeted treatment decisions. The value proposition to rheumatologists is clear: reduced diagnostic uncertainty translates directly into better patient management.

The higher average selling prices achieved in the quarter are a function of both favourable payor mix and Exagen's ongoing efforts to expand reimbursement coverage and negotiate better contract terms. Diagnostic companies often find that revenue growth has two engines — volume and price — and that sustainable commercial expansion requires both. The simultaneous improvement in both metrics in Q1 suggests that Exagen's commercial and managed care teams are executing effectively on multiple fronts.

The improving adjusted EBITDA performance is the figure that changes the Investment narrative most meaningfully. A diagnostics company that is growing revenue at double-digit rates while simultaneously moving towards profitability is executing the playbook that the sector rewards with higher multiples and greater institutional interest. Cash burn reduction matters not only for the obvious reason that it preserves Balance Sheet flexibility, but also because it signals that the business model is beginning to demonstrate Operating Leverage — the condition under which fixed costs are absorbed by growing revenues and incremental sales flow more directly to the Bottom Line.

The maintenance of full-year revenue guidance at $70 to $73 million is, in context, a modest statement of confidence. A company that posts a record quarter and reaffirms guidance is effectively telling the market that Q1 was not an anomaly — that the underlying drivers of growth are structural rather than seasonal. Investors appear to have taken that message at Face Value.

This article is for informational purposes only and does not constitute investment advice.